Keyword: Ron Wyden

Complacent about drug-pricing action in Congress? Despite the chaos of impeachment and elections, lawmakers are still taking drug pricing seriously.

D.C. is buzzing with flashy proposals to confront drug prices. All of them face big hurdles—including pharma’s lobbying prowess.

After Mylan's high-profile EpiPen misclassification, lawmakers have passed a bill cracking down on Medicaid misrepresentations that cost taxpayers.

Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.

Citing Mylan's EpiPen, two senators introduced a bill cracking down on drug misclassifications that cost Medicaid millions in underpaid rebates.

Sen. Ron Wyden wants to know more about why Pfizer CEO Ian Read agreed to defer the company's July price hikes.

AbbVie has stored dozens of Humira patents in Bermuda, allowing it to lower its corporate tax rate, according to Reuters.

If Novartis thought public statements this week would silence questions about its $1.2 million contract with Michael Cohen, it was wrong.

President Donald Trump tweeted his nomination for ex-Eli Lilly executive Alex Azar as HHS secretary Monday morning.

If President Donald Trump can’t count on Congress to pass pricing legislation, his administration may go it alone.